By SPC News Staff
The FDA approved sutimlimab-jome (Enjaymo, Sanofi) infusion to decrease the need for red blood cell transfusion due to hemolysis in adults with cold agglutinin disease (CAD).
Sutimlimab-jome, a humanized monoclonal antibody (mAB), is the first and only approved treatment for people with CAD and works by inhibiting the destruction of red blood cells.